ArticleACR open rheumatology2022

Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.

Shervin Assassi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.